Ear-Based Vagus Nerve Stimulation Shows Promise for Chronic Jaw Pain Relief

Temporomandibular disorders (TMD) rank as the second most common chronic musculoskeletal pain condition worldwide, affecting 6–9% of adults and disproportionately burdening women aged 20–40, veterans, and those with comorbid mental health conditions. Chronic TMD involves complex interactions between jaw muscle pain, autonomic nervous system dysregulation, and psychological distress — making it a compelling target for neuromodulation therapies like vagus nerve stimulation.

Transcutaneous auricular vagus nerve stimulation (taVNS) offers a non-invasive alternative to surgically implanted VNS. By stimulating the auricular branch of the vagus nerve at the cymba conchae of the left ear, taVNS activates the nucleus tractus solitarii and cascades signals through subcortical and cortical regions governing pain perception, inflammation, and emotional regulation. It carries CE certification for epilepsy, depression, chronic pain, and anxiety, and has shown efficacy across several conditions sharing pathophysiology with TMD, including migraine, fibromyalgia, and tinnitus.

This parallel-arm, participant-blinded pilot RCT enrolled 20 adults with Grade III or IV chronic TMD pain (per the von Korff Graduation of Chronic Pain Scale) at the University Medical Center Düsseldorf. Participants were randomized 1:1 to active taVNS (left tragus/cymba conchae, 25 Hz, 250 μs pulse width, 28s-on/32s-off, 4 hours/day) or an inactive sham electrode identical in appearance. Outcomes were assessed at baseline, 4 weeks, and 8 weeks using validated patient-reported measures — GCPS, PHQ-9 (depression), GAD-7 (anxiety), PHQ-15 (somatic symptoms), and OHIP-G14 (oral health quality of life) — plus electromyographic muscle activity and jaw kinematic measurements. Compliance was tracked via a smartphone app.

Feasibility was robustly demonstrated: recruitment rate was 100%, retention 90%, and daily adherence to the 4-hour stimulation protocol reached 83%. The taVNS group exhibited a large effect size on oral health-related quality of life (OHIP-G14), and at least small but potentially clinically meaningful effects on pain intensity, anxiety, depression, somatic symptom severity, masseter muscle EMG activity, and jaw kinematics compared to the sham group. Crucially, none of these differences achieved statistical significance, which is expected and acceptable in a pilot study of this size — the primary goal being feasibility, not definitive efficacy. No serious adverse events were reported in either group.

These findings are clinically encouraging for several reasons. taVNS targets the autonomic imbalance (excess sympathetic tone) implicated in TMD pain amplification, and the multi-domain improvements — spanning pain, mood, function, and muscle physiology — suggest a plausible biological mechanism rather than nonspecific response. The strong adherence rates also indicate patient acceptability of a 4-hour daily home-use protocol. The authors recommend a larger, fully powered RCT with extended follow-up to establish definitive efficacy, optimal stimulation parameters, and long-term safety.